.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Farmers Insurance
Cipla
Citi
Chinese Patent Office
Covington
Cerilliant
Baxter
Chubb
McKesson

Generated: September 20, 2017

DrugPatentWatch Database Preview

INCRELEX Drug Profile

« Back to Dashboard

Which patents cover Increlex, and what generic Increlex alternatives are available?

Increlex is a drug marketed by Ipsen Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-nine patent family members in fifteen countries.

The generic ingredient in INCRELEX is mecasermin recombinant. One supplier is listed for this compound. Additional details are available on the mecasermin recombinant profile page.

Summary for Tradename: INCRELEX

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list14
Drug Prices:see details
DailyMed Link:INCRELEX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839-001Aug 30, 2005RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INCRELEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839-001Aug 30, 2005► Subscribe► Subscribe
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839-001Aug 30, 2005► Subscribe► Subscribe
Ipsen Inc
INCRELEX
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839-001Aug 30, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: INCRELEX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,126,324 Method of enhancing growth in patients using combination therapy► Subscribe
5,597,898 NF-.kappa.B activation regulatory protein, I.kappa.B-.beta.► Subscribe
5,597,802 Method of formulating IGF-I with growth hormone► Subscribe
5,597,797 Method for treatment or prevention of obesity► Subscribe
5,374,620 Growth-promoting composition and its use► Subscribe
5,849,580 Nucleic acid encoding a NF-.kappa.B activation regulatory protein, I.kappa.B.beta.► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: INCRELEX

Country Document Number Estimated Expiration
Denmark0669832► Subscribe
Germany69305091► Subscribe
Moldova, Republic of960245► Subscribe
Denmark0536226► Subscribe
Tajikistan286► Subscribe
Austria143267► Subscribe
Brazil1100122► Subscribe
Austria141799► Subscribe
Canada2083159► Subscribe
European Patent Office0669832► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Medtronic
Chinese Patent Office
US Army
Merck
Baxter
Fish and Richardson
Dow
Chubb
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot